XOMA Royalty (XOMA) Total Non-Current Liabilities (2010 - 2026)

XOMA Royalty's (XOMA) quarterly Total Non-Current Liabilities came in at $155.3 million in Q1 2026, up 24.39% year-on-year from $124.8 million in Q1 2025, and down 5.98% quarter-over-quarter from $165.1 million in Q4 2025.

XOMA Royalty (XOMA) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends

XOMA Royalty has disclosed Total Non-Current Liabilities across 16 years of filings, most recently posting $155.3 million for Q1 2026.

  • Total Non-Current Liabilities for Q1 2026 came in at $155.3 million, up 24.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $155.3 million (up 24.39% YoY), and the FY2025 annual result was $165.1 million, up 21.3% from the prior year.
  • Total Non-Current Liabilities came in at $155.3 million for Q1 2026 at XOMA Royalty, down from $165.1 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $165.1 million in Q4 2025 to a low of $15.0 million in Q1 2023.
  • The 4-year median for Total Non-Current Liabilities is $136.1 million (2024), against an average of $127.9 million.
  • Across the five-year window, Total Non-Current Liabilities retreated 9.09% in 2025 and gained 24.39% in 2026, its largest moves.
  • XOMA Royalty's Total Non-Current Liabilities stood at $15.0 million in 2023, then surged by 807.25% to $136.1 million in 2024, then climbed by 21.3% to $165.1 million in 2025, then declined by 5.98% to $155.3 million in 2026.
  • The last three Total Non-Current Liabilities figures came in at $155.3 million (Q1 2026), $165.1 million (Q4 2025), and $151.7 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Alterity Therapeutics 788,338.31 Bn 788,338.28 Bn - 42,980.09
2 Belite Bio 56,560.00 Bn 56,560.00 Bn - -
3 Quantum Biopharma 17,329.30 Bn 17,329.30 Bn - 11.03 Mn
4 Legend Biotech 3,341.00 Bn 3,340.71 Bn 242.10 Mn 95.20 Mn
5 Akari Therapeutics 1,727.91 Bn 1,727.91 Bn - -
6 Evaxion A 1,536.68 Bn 1,536.67 Bn - -
7 Psyence Biomedical 238.34 Bn 238.33 Bn - 644,700.00
8 Vertex Pharmaceuticals 113.42 Bn 106.17 Bn 2.59 Bn 5.87 Bn
9 Abivax 95.45 Bn 95.45 Bn - 64.76 Mn
10 XOMA Royalty 5.52 Mn -60.56 Mn - 155.26 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 155.26 Mn
Dec 31, 2025 165.14 Mn
Sep 30, 2025 151.69 Mn
Jun 30, 2025 127.60 Mn
Mar 31, 2025 124.81 Mn
Dec 31, 2024 136.14 Mn
Sep 30, 2024 135.41 Mn
Jun 30, 2024 140.37 Mn
Mar 31, 2023 15.01 Mn
Sep 30, 2021 18.90 Mn
Jun 30, 2021 19.15 Mn
Mar 31, 2021 38.07 Mn
Dec 31, 2020 38.81 Mn
Sep 30, 2020 47.55 Mn
Jun 30, 2020 49.43 Mn
Mar 31, 2020 50.47 Mn
Dec 31, 2019 51.69 Mn
Sep 30, 2019 59.85 Mn
Jun 30, 2019 57.05 Mn
Mar 31, 2019 51.61 Mn